116 related articles for article (PubMed ID: 25765978)
21. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
[TBL] [Abstract][Full Text] [Related]
23. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice.
Lee TY; Kim YH; Lee KS; Kim JK; Lee IH; Yang JM; Sung MH; Park JS; Poo H
Cancer Immunol Immunother; 2010 Nov; 59(11):1727-37. PubMed ID: 20706715
[TBL] [Abstract][Full Text] [Related]
25. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells.
Lea JS; Sunaga N; Sato M; Kalahasti G; Miller DS; Minna JD; Muller CY
Reprod Sci; 2007 Jan; 14(1):20-8. PubMed ID: 17636212
[TBL] [Abstract][Full Text] [Related]
26. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
27. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670
[TBL] [Abstract][Full Text] [Related]
28. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
[TBL] [Abstract][Full Text] [Related]
29. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice.
Decrausaz L; Revaz V; Bobst M; Corthésy B; Romero P; Nardelli-Haefliger D
Int J Cancer; 2010 May; 126(10):2469-78. PubMed ID: 19816937
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
31. TLR9 expression in uterine cervical lesions of Uyghur women correlate with cervical cancer progression and selective silencing of human papillomavirus 16 E6 and E7 oncoproteins in vitro.
Hao Y; Yuan JL; Abudula A; Hasimu A; Kadeer N; Guo X
Asian Pac J Cancer Prev; 2014; 15(14):5867-72. PubMed ID: 25081715
[TBL] [Abstract][Full Text] [Related]
32. HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m
Hu C; Liu T; Han C; Xuan Y; Jiang D; Sun Y; Zhang X; Zhang W; Xu Y; Liu Y; Pan J; Wang J; Fan J; Che Y; Huang Y; Zhang J; Ding J; Yang S; Yang K
Int J Biol Sci; 2022; 18(2):507-521. PubMed ID: 35002506
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.
Kennedy EM; Kornepati AV; Goldstein M; Bogerd HP; Poling BC; Whisnant AW; Kastan MB; Cullen BR
J Virol; 2014 Oct; 88(20):11965-72. PubMed ID: 25100830
[TBL] [Abstract][Full Text] [Related]
34. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
[TBL] [Abstract][Full Text] [Related]
35. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
36. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
37. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
Persson M; Brismar Wendel S; Ljungblad L; Johansson B; Weiderpass E; Andersson S
Oncol Rep; 2012 Jul; 28(1):346-52. PubMed ID: 22484610
[TBL] [Abstract][Full Text] [Related]
38. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
39. Oral Administration of Poly-Gamma-Glutamic Acid Significantly Enhances the Antitumor Effect of HPV16 E7-Expressing
Kim E; Yang J; Sung MH; Poo H
J Microbiol Biotechnol; 2019 Sep; 29(9):1444-1452. PubMed ID: 31387341
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]